Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Epigenetic Instability: A novel biomarker for cancer and clonality

FY 2022-23

Summary
The hematopoietic (blood) system and all of its components are generated by a small group of cells called hematopoietic stem/progenitor cells (HSPCs). As humans age, HSPCs start to incur mutations in their DNA which results in clonal hematopoiesis (CH), a condition where some HSPCs make a greater contribution to the blood cell pool by reproducing more efficiently than others. CH is associated with an increased risk of developing blood cancer (known as leukemia) as well as other health complications. Thus, detecting clonal expansion of abnormal cells is critical for early detection of leukemia and monitoring the progress of the disease. Current methods to detect CH rely on genome sequencing, but this is too costly for widespread use in hospitals and clinics. The “epigenome” – a term that refers to chemical modifications of the genome such as DNA methylation (DNA-M) – represents an additional layer of information that can be used to study diseases. Fast and inexpensive methods have recently emerged to measure DNA-M, making them ideal for use in clinical testing. However, not much is known about DNA-M in relation to CH. The goal of this project is to develop a way to detect CH by using DNA-M information. By studying what DNA-M looks like in the blood of young, healthy individuals and comparing it to the DNA-M profiles of blood cancer patients, I will characterize the differences and use them to devise a novel measurement of “epigenetic instability”. This biological indicator could be used by clinicians for earlier detection of leukemia and more sensitive monitoring of patients who have it, thereby improving quality of life for the thousands of people who are affected by this devastating disease.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486464
Name
Basrai Salman
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Epigenetic Instability: A novel biomarker for cancer and clonality
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Aging; Biomarker; Cancer; Clonality; Disease Monitoring; Dna Methylation; Early Cancer Detection; Epigenetics; Hematopoiesis; Leukemia
Abstract
The hematopoietic (blood) system and all of its components are generated by a small group of cells called hematopoietic stem/progenitor cells (HSPCs). As humans age, HSPCs start to incur mutations in their DNA which results in clonal hematopoiesis (CH), a condition where some HSPCs make a greater contribution to the blood cell pool by reproducing more efficiently than others. CH is associated with an increased risk of developing blood cancer (known as leukemia) as well as other health complications. Thus, detecting clonal expansion of abnormal cells is critical for early detection of leukemia and monitoring the progress of the disease. Current methods to detect CH rely on genome sequencing, but this is too costly for widespread use in hospitals and clinics. The “epigenome” – a term that refers to chemical modifications of the genome such as DNA methylation (DNA-M) – represents an additional layer of information that can be used to study diseases. Fast and inexpensive methods have recently emerged to measure DNA-M, making them ideal for use in clinical testing. However, not much is known about DNA-M in relation to CH. The goal of this project is to develop a way to detect CH by using DNA-M information. By studying what DNA-M looks like in the blood of young, healthy individuals and comparing it to the DNA-M profiles of blood cancer patients, I will characterize the differences and use them to devise a novel measurement of “epigenetic instability”. This biological indicator could be used by clinicians for earlier detection of leukemia and more sensitive monitoring of patients who have it, thereby improving quality of life for the thousands of people who are affected by this devastating disease.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Basrai, Salman
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~